Literature DB >> 3657703

The treatment of neuroblastoma with 131I-MIBG.

R Mastrangelo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3657703     DOI： 10.1002/mpo.2950150403

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  5 in total

1.  Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma.

Authors:  R Mastrangelo; A Tornesello; A Lasorella; A Iavarone; S Mastrangelo; R Riccardi; L Diociaiuti; V Rufini; A Pession; L Troncone
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  A human neuroblastoma xenograft model for 125-I-metaiodobenzylguanidine biodistribution studies.

Authors:  M Lavitrano; T Servidei; S Mastrangelo; A Tornesello; D Fioretti; C Di Stefano; A Riccardi; R Franceschini; R Riccardi
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.

Authors:  S Mastrangelo; A Tornesello; L Diociaiuti; A Pession; A Prete; V Rufini; L Troncone; R Mastrangelo
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

4.  Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.

Authors:  S H Cunningham; R J Mairs; T E Wheldon; P C Welsh; G Vaidyanathan; M R Zalutsky
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

5.  Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

Authors:  G Vaidyanathan; H S Friedman; S T Keir; M R Zalutsky
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.